FDA Leadership Turmoil Escalates as Richard Pazdur Takes CDER Helm Amid Pfizer-Novo Bidding War
Key Insights
FDA veteran Richard Pazdur (search) has accepted the director role at the Center for Drug Evaluation and Research (CDER), replacing George Tidmarsh who left amid conflict with biologics chief Vinay Prasad.
Internal FDA tensions have reached a breaking point, with sources warning of potential mass resignations if Prasad attempts to supersede Pazdur's authority at the drug evaluation center.
Pfizer emerged victorious in the high-stakes bidding war with Novo Nordisk for obesity (search) biotech Metsera, while a separate acquisition battle has erupted between Lundbeck and Alkermes for sleep company Avadel Pharmaceuticals.
The FDA's leadership crisis deepened this week as veteran regulator Richard Pazdur (search) stepped into the director role at the Center for Drug Evaluation and Research (CDER), taking over from George Tidmarsh who departed amid escalating conflicts with Center for Biologics Evaluation and Research (CBER (search)) Director Vinay Prasad.
FDA Internal Conflicts Reach Breaking Point
The appointment of Pazdur, a 26-year FDA veteran widely regarded as a highly respected and thoughtful regulator, comes at a critical juncture for the agency. Sources familiar with the situation told BioSpace that if Prasad attempts to supersede Pazdur's authority, "there will be hell to pay and resignations to be handed in."
The tensions stem from a slow-boiling feud between Prasad, who heads the FDA's biologics and vaccine branch, and his staff that has triggered additional exits and plunging morale. The conflict has been further complicated by personal animosity, with reports indicating that Prasad and the departed Tidmarsh "hate each other."
Tidmarsh's shocking exit followed accusations that he used his regulatory position to exact personal revenge against a former business partner, adding another layer of controversy to the agency's current turmoil.
Pfizer Wins Metsera Bidding War
In the pharmaceutical M&A arena, Pfizer emerged victorious in the highly publicized bidding war with Novo Nordisk for obesity (search) biotech Metsera. The acquisition battle, which saw escalating bids and flaring tempers, concluded with Pfizer securing the coveted target in what industry observers described as everyone's favorite obesity drug bidding war.
The competition for Metsera reflects the intense interest in obesity (search) therapeutics, with both pharmaceutical giants recognizing the significant market potential in this therapeutic area.
New Bidding War Emerges
Even as the Metsera deal concluded, another acquisition battle has erupted in the pharmaceutical sector. Lundbeck and Alkermes are now engaged in a separate bidding war for sleep biotech Avadel Pharmaceuticals, demonstrating continued robust M&A activity in specialized therapeutic areas.
Sarepta Gene Therapy Receives Black Box Warning
The FDA formally concluded one of the year's most controversial regulatory decisions by adding a black box warning to Sarepta Therapeutics' gene therapy Elevidys. The warning addresses serious liver toxicities (search) and risk of death associated with the treatment, while the agency also removed the nonambulatory indication from the drug's label.
As part of the regulatory action, the FDA will require Sarepta to complete a postmarketing observational study involving approximately 200 patients to further assess the therapy's safety profile.
Broader M&A Activity Continues
The pharmaceutical industry's acquisition momentum has continued with several major deals beyond the Metsera transaction. Merck (search) announced a substantial $9.2 billion buyout of Cidara Therapeutics, while Johnson & Johnson made a $3 billion investment in Halda Therapeutics (search), highlighting the ongoing consolidation trend in the biotech sector.
Additional FDA Developments
The leadership changes occur against a backdrop of broader FDA developments, including Commissioner Marty Makary's apparent conflicts with Health Secretary Robert F. Kennedy Jr. The agency has also revealed additional details about its plausible mechanisms pathway, which Makary had previously teased during his tenure.